A. C. via Unsplash+Belgian Coultreon Biopharma has raised US$125m in a big‑pharma‑backed Series A round to push its first‑in‑class SIK3 inhibitor into Phase II after an ongoing Phase I programme in autoimmune disease
Tag Archive for: Autoimmune diseases
adobe stock photos - JHVEPhotoSanofi SA has received FDA marketing approval for Wayrilz (rilzabrutinib). Unlike three existing causal treatments for immune thrombocytopenia (ITP), the oral drug inhibits both processes that drive the autoimmune disease. Analysts therefore predict peak sales twice as high as those of previously approved ITP drugs.